<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367805</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0042</org_study_id>
    <nct_id>NCT04367805</nct_id>
  </id_info>
  <brief_title>COVID-19 Infection in Patients With Hepatocellular Carcinoma</brief_title>
  <acronym>COVID19-CHIEF</acronym>
  <official_title>Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier-Universitaire Bondy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier-Universitaire CLICHY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Général CORBEIL-ESSONNE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU CRETEIL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU LYON</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU VILLEJUIF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has
      emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5
      continents, and responsible for a pandemic. France is the third most affected country in
      Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form
      of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer
      or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described
      with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19
      infection for compensated or decompensated cirrhotic patients. The objectives of this project
      are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both
      hospital and ambulatory, and to study the impact on the frequency of severe forms, the
      prognosis, but also liver function, and the management of hepatocellular carcinoma, in this
      context of pandemic
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>COVID-19</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>nasopharyngeal Covid 19 RT-PCR</intervention_name>
    <description>nasopharyngeal Covid 19 RT-PCR</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hepatocellular carcinoma population, both hospital and ambulatory
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CHC and included in the French national prospective cohort CHIEF

          -  Hospital and ambulatory patients

          -  Infection confirmed by COVID-19 defined by a positive nasopharyngeal PCR or if PCR
             COVID-19 negative : CT showing COVID-19 compatible pneumonia

          -  Suspected COVID-19 infection, not confirmed by COVID-19 PCR or chest CT, with no other
             known cause of acute pneumonia.

        Exclusion Criteria:

          -  Patient refusal

          -  Influenza only, confirmed by a diagnostic test

          -  Other proven causes of pneumonia and absence of COVID-19
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric NGUYEN KHAC, Pr</last_name>
    <phone>(33)3 22 08 88 51</phone>
    <email>nguyen-khac.eric@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier GANRY, Pr</last_name>
    <phone>(33)3 22 08 83 76</phone>
    <email>ganry.olivier@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric NGUYEN KHAC, Pr</last_name>
      <phone>(33)3 22 08 88 51</phone>
      <email>nguyen-khac.eric@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier Ganry, Pr</last_name>
      <phone>(33)322668193</phone>
      <email>ganry.olivier@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nathalie GANNE-CARRIE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Frédéric BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed BOUATTOUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurore BARON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuliana AMADDEO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas DECAENS, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe MATHURIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe MERLE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine SILVAIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien EDELINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre MICHEL, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie PERON, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Éric VIBERT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Pierre BRONOWICKI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodolphe ANTY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric ASSENAT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus disease 2019-Incidence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

